Sarepta Therapeutics Company Profile (NASDAQ:SRPT)

About Sarepta Therapeutics

Sarepta Therapeutics logoSarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases. The Company's lead Duchenne Muscular Dystrophy (DMD) product candidate, Eteplirsen, is an antisense phosphorodiamidate morpholino oligomer (PMO) therapeutic in Phase III clinical development for the treatment of individuals with DMD having an error in the gene coding for dystrophin that is amenable to skipping exon 51.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: SRPT
  • CUSIP:
Key Metrics:
  • Previous Close: $32.02
  • 50 Day Moving Average: $31.03
  • 200 Day Moving Average: $36.26
  • 52-Week Range: $54,590,000.00 - $8.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -14.89
  • P/E Growth: 29.20
  • Market Cap: $1.75B
  • Outstanding Shares: 54,590,000
  • Beta: 1.87
  • Return on Equity: -97.14%
  • Return on Assets: -73.56%
  • Debt-to-Equity Ratio: 0.02%
  • Current Ratio: 6.70%
  • Quick Ratio: 6.65%
Additional Links:
Companies Related to Sarepta Therapeutics:

Analyst Ratings

Consensus Ratings for Sarepta Therapeutics (NASDAQ:SRPT) (?)
Ratings Breakdown: 1 Sell Rating, 4 Hold Ratings, 13 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.74)
Consensus Price Target: $62.00 (93.63% upside)

Analysts' Ratings History for Sarepta Therapeutics (NASDAQ:SRPT)
DateFirmActionRatingPrice TargetDetails
2/22/2017Needham & Company LLCLower Price TargetBuy -> Buy$81.00 -> $78.00View Rating Details
2/21/2017Robert W. BairdReiterated RatingOutperform$102.00View Rating Details
2/21/2017Leerink SwannReiterated RatingMarket PerformView Rating Details
2/16/2017Oppenheimer Holdings, Inc.Reiterated RatingOutperform$76.00View Rating Details
1/12/2017Cowen and CompanyReiterated RatingOutperform$62.00View Rating Details
1/11/2017Jefferies Group LLCReiterated RatingHoldView Rating Details
1/7/2017Credit Suisse GroupReiterated RatingOutperform$66.00View Rating Details
1/6/2017JMP SecuritiesLower Price TargetOutperform$160.00 -> $65.00View Rating Details
1/4/2017Morgan StanleyLower Price TargetEqual -> Weight$53.00 -> $33.00View Rating Details
1/3/2017Janney Montgomery ScottUpgradeNeutral -> Buy$27.43 -> $65.00View Rating Details
12/22/2016J P Morgan Chase & CoInitiated CoverageOverweight$40.00View Rating Details
12/20/2016Goldman Sachs Group, Inc. (The)Initiated CoverageNeutral$40.00View Rating Details
12/16/2016RBC Capital MarketsSet Price TargetBuy$106.00 -> $98.00View Rating Details
12/16/2016Royal Bank of CanadaBoost Price TargetOutperform$98.00 -> $106.00View Rating Details
10/27/2016Piper Jaffray CompaniesReiterated RatingBuyView Rating Details
10/27/2016WedbushReiterated RatingOutperform$72.00View Rating Details
10/17/2016SunTrust Banks, Inc.Reiterated RatingHold$52.00View Rating Details
10/2/2016William BlairReiterated RatingOutperform$88.00View Rating Details
9/20/2016WBB SecuritiesReiterated RatingStrong-Buy$40.00 -> $60.00View Rating Details
5/5/2016Ladenburg Thalmann Financial ServicesDowngradeMarket Perform -> Underperform$13.00 -> $5.00View Rating Details
11/8/2015Roth CapitalReiterated RatingBuy$50.00View Rating Details
10/23/2015Bank of America CorpInitiated CoverageBuy$49.00View Rating Details
9/1/2015Susquehanna Bancshares IncBoost Price TargetNeutral$33.00 -> $36.00View Rating Details
5/23/2015Deutsche Bank AGReiterated RatingHold$24.00View Rating Details
5/20/2015Canaccord GenuityUpgradeHold -> Buy$16.00 -> $30.00View Rating Details
(Data available from 2/26/2015 forward)


Earnings History for Sarepta Therapeutics (NASDAQ:SRPT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2017Q416($1.33)$4.86 millionListenView Earnings Details
10/27/2016Q316($1.32)($0.95)$1.06 millionViewListenView Earnings Details
7/19/2016Q2($1.19)($1.35)ViewN/AView Earnings Details
5/5/2016Q1($1.30)($1.15)$0.18 millionViewN/AView Earnings Details
2/24/2016Q4($1.18)($1.30)$1.25 millionViewN/AView Earnings Details
11/5/2015Q315($1.19)($1.25)ViewListenView Earnings Details
8/6/2015Q215($1.21)($1.01)$0.31 million$0.01 millionViewListenView Earnings Details
5/7/2015Q115($1.00)($1.49)$0.78 millionViewListenView Earnings Details
2/26/2015Q414($0.82)($0.94)$1.56 million$0.30 millionViewListenView Earnings Details
11/6/2014Q314($0.96)($0.70)$3.07 million$1.10 millionViewListenView Earnings Details
8/7/2014Q214($0.76)($0.85)$4.30 million$2.58 millionViewListenView Earnings Details
5/8/2014Q114($0.80)($0.75)$3.45 million$6.09 millionViewListenView Earnings Details
2/27/2014Q413($0.69)($0.77)$4.53 million$2.60 millionViewListenView Earnings Details
11/12/2013Q313($0.65)($0.63)$4.57 million$4.20 millionViewListenView Earnings Details
8/8/2013Q2 2013($0.67)($0.46)$5.08 million$3.00 millionViewListenView Earnings Details
5/9/2013Q1 2013($0.62)($0.41)$5.85 million$4.50 millionViewListenView Earnings Details
3/7/2013Q4 2012($0.26)($2.36)$6.71 million$7.30 millionViewListenView Earnings Details
11/7/2012($0.27)($2.17)$10.06 million$7.57 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Sarepta Therapeutics (NASDAQ:SRPT)
Current Year EPS Consensus Estimate: $-5.16 EPS
Next Year EPS Consensus Estimate: $-2.15 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($1.40)($1.17)($1.29)
Q2 20165($1.32)($0.62)($1.08)
Q3 20166($1.41)($0.59)($1.10)
Q4 20166($1.51)($0.47)($1.05)
Q1 20172($1.15)($0.98)($1.07)
Q2 20172($1.02)($0.87)($0.95)
Q3 20172($0.99)($0.70)($0.85)
Q4 20172($0.97)($0.53)($0.75)
(Data provided by Zacks Investment Research)


Dividend History for Sarepta Therapeutics (NASDAQ:SRPT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Sarepta Therapeutics (NASDAQ:SRPT)
Insider Ownership Percentage: 10.90%
Institutional Ownership Percentage: 76.75%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/17/2016Sandesh MahatmeInsiderSell30,000$50.08$1,502,400.00View SEC Filing  
9/22/2016David T HowtonSVPSell7,000$60.00$420,000.00View SEC Filing  
9/22/2016Edward M Md KayeCEOSell40,179$60.00$2,410,740.00View SEC Filing  
9/19/2016David T HowtonSVPSell9,304$50.00$465,200.00View SEC Filing  
9/19/2016Edward M Md KayeCEOSell24,352$50.00$1,217,600.00View SEC Filing  
9/19/2016Jayant AphaleVPSell35,000$50.00$1,750,000.00View SEC Filing  
9/14/2016Edward M Md KayeCEOSell24,557$30.00$736,710.00View SEC Filing  
3/16/2016M Kathleen BehrensDirectorBuy10,000$14.54$145,400.00View SEC Filing  
3/14/2016M Kathleen BehrensDirectorBuy65,000$16.54$1,075,100.00View SEC Filing  
11/14/2013Anthony ChaseDirectorBuy10,000$13.95$139,500.00View SEC Filing  
9/16/2013M Kathleen BehrensDirectorBuy6,500$37.04$240,760.00View SEC Filing  
9/3/2013John HodgmanDirectorSell5,556$34.97$194,293.32View SEC Filing  
8/22/2013Anthony ChaseDirectorBuy3,500$32.68$114,380.00View SEC Filing  
8/20/2013Sandesh MahatmeCFOBuy5,000$31.10$155,500.00View SEC Filing  
6/14/2013Anthony R ChaseDirectorBuy10,000$38.50$385,000.00View SEC Filing  
9/7/2012M Kathleen BehrensDirectorBuy17,500$14.73$257,775.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Sarepta Therapeutics (NASDAQ:SRPT)
DateHeadline logoCommit To Purchase Sarepta Therapeutics At $18, Earn 16.7% Using Options (NASDAQ:SRPT) - February 24 at 10:49 PM
News IconEPS Of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) At $-1.26 ... - Stock Observer (NASDAQ:SRPT) - February 23 at 8:12 PM logoPoint72 Asset Management, LP Raises Stake in Sarepta Therapeutics (SRPT) to 5.2% - (NASDAQ:SRPT) - February 23 at 8:12 PM
News IconAnalysts Peeling Back The Layers on Sarepta Therapeutics, Inc. (NASDAQ:SRPT): Consensus Take - Winfield Review (NASDAQ:SRPT) - February 23 at 8:12 PM
News IconIndicator Level Summary for Sarepta Therapeutics Inc (SRPT) - Baldwin Journal (NASDAQ:SRPT) - February 23 at 8:12 PM
News Icon$SRPT Stock Chart Breakout, Major Upside Possible (NASDAQ:SRPT) - February 22 at 8:11 PM logoSarepta Therapeutics, Inc. (NASDAQ:SRPT) Files An 8-K Entry into a Material Definitive Agreement (NASDAQ:SRPT) - February 22 at 8:11 PM logoThe Contrary Indicators Are Piling Up (NASDAQ:SRPT) - February 22 at 8:11 PM logoBull Market Ahead for the Biotech Industry in 2017? Today's Reports on Sarepta Therapeutics and Galectin Therapeutics (NASDAQ:SRPT) - February 22 at 10:04 AM logoSarepta sells Priority Review Voucher for US$125mln (NASDAQ:SRPT) - February 21 at 4:54 PM
News IconSarepta Auctions Off Its Priority Review Voucher for Exondys 51 to Gilead for $125 Million (NASDAQ:SRPT) - February 21 at 4:54 PM
News IconPreview of Stock Movement: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) (NASDAQ:SRPT) - February 21 at 4:54 PM logoSarepta Therapeutics (SRPT) to Sell PRV Voucher for $125M (NASDAQ:SRPT) - February 21 at 4:54 PM logoSarepta Sells Priority Review Voucher for $125M (SRPT) (NASDAQ:SRPT) - February 21 at 4:54 PM logoSarepta Therapeutics Agrees to Sale of Priority Review Voucher for $125M (NASDAQ:SRPT) - February 21 at 4:54 PM logo7:03 am Sarepta Therapeutics enters into an agreement to sell its Rare Pediatric Disease Priority Review Voucher for $125 million (NASDAQ:SRPT) - February 21 at 4:54 PM logoSAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E (NASDAQ:SRPT) - February 21 at 4:54 PM logoSarepta sells FDA review voucher for $125M, but analyst questions price (NASDAQ:SRPT) - February 21 at 4:54 PM logoSarepta Sells Priority Review Voucher for $125M (NASDAQ:SRPT) - February 21 at 4:54 PM logoDid Gilead's new tool for speeding drug approval come at bargain-basement price? (NASDAQ:SRPT) - February 21 at 2:10 PM
News IconThis Weeks Target Prices For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) (NASDAQ:SRPT) - February 18 at 8:51 AM
News IconAnalysts believe Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is worth $62.89 per share (NASDAQ:SRPT) - February 18 at 8:51 AM logoSanthera opens Mass. office as local Duchenne ecosystem grows (NASDAQ:SRPT) - February 17 at 7:23 PM logoCongressman Keating calls pricy Duchenne drug an example of 'gouging' (NASDAQ:SRPT) - February 17 at 7:23 PM logoOppenheimer Stays Bullish on Sarepta Therapeutics Inc (SRPT) as the Stock Shows Signs of Weakness (NASDAQ:SRPT) - February 16 at 7:46 PM logoSarepta Therapeutics to Announce Fourth Quarter and Full-Year 2016 Financial Results and Recent Corporate Developments on February 28, 2017 (NASDAQ:SRPT) - February 16 at 7:46 PM logoOppenheimer Stays Bullish On Sarepta As Concerns Continue To Swirl (NASDAQ:SRPT) - February 16 at 7:46 PM logoDefending Sarepta Against Blowback From the Marathon Pharma Steroid Price Gouging Scandal (NASDAQ:SRPT) - February 15 at 6:10 AM
News IconNews Impact Score Of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) At 100 - Stock Observer (NASDAQ:SRPT) - February 14 at 6:30 AM
News IconIs Sarepta Therapeutics, Inc. (SRPT) Preparing For A Breakout Trade? - Post Analyst (NASDAQ:SRPT) - February 14 at 6:30 AM logoMarathon Pharma will pause launch of Duchenne muscular dystrophy drug after outcry over $89,000 price (NASDAQ:SRPT) - February 14 at 6:30 AM logoStocks To Track: Community Health Systems, Inc. (CYH), Sarepta Therapeutics, Inc. (SRPT), Gannett Co., Inc. (GCI) - iStreetWire (NASDAQ:SRPT) - February 13 at 8:06 AM logoSarepta Muscular Dystrophy Drug Gets Competition (SRPT) (NASDAQ:SRPT) - February 11 at 3:39 AM logoSarepta Muscular Dystrophy Drug Faces Competition (NASDAQ:SRPT) - February 11 at 3:39 AM logoFDA approves Marathon Pharma's Duchenne muscular dystrophy drug (NASDAQ:SRPT) - February 10 at 4:59 AM
News IconStock Upsurging Yielding Gains in Session Sarepta Therapeutics, Inc. (NASDAQ:SRPT) (NASDAQ:SRPT) - February 8 at 6:18 AM
News IconStock Upsurging Yielding Gains in Session Sarepta Therapeutics, Inc. (NASDAQ:SRPT) (NASDAQ:SRPT) - February 8 at 6:18 AM logoWhy Sarepta Therapeutics, Inc. Stock Rose 13.2% in January (NASDAQ:SRPT) - February 6 at 4:31 PM
News IconEarnings Forecast Research on Sarepta Therapeutics, Inc. (SRPT) - Highland Mirror (NASDAQ:SRPT) - February 3 at 5:41 AM logoForget GW Pharmaceuticals -- These 2 Stocks Are Better Buys (NASDAQ:SRPT) - February 2 at 10:58 AM logoStock Update (NASDAQ:SRPT): Sarepta Therapeutics Inc Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (NASDAQ:SRPT) - February 2 at 4:35 AM logoSarepta: It's Not Whether Insurers Will Pay. It's How Much They'll Pay (NASDAQ:SRPT) - February 2 at 4:35 AM logoSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (NASDAQ:SRPT) - February 1 at 6:18 AM
News IconWhat are Analysts Expecting for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Earnings? - Aiken Advocate (NASDAQ:SRPT) - January 30 at 10:10 PM
News IconStock Survey: Viewing Levels for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - The Tribune (NASDAQ:SRPT) - January 30 at 7:34 AM
News IconTechnical Watch on These Shares: Sarepta Therapeutics Inc. (SRPT) - Springdale Times (NASDAQ:SRPT) - January 28 at 6:44 AM
News IconEarnings in Full Force, Analysts Take Aim at Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Wall Street Beacon (NASDAQ:SRPT) - January 27 at 4:01 AM logoSRPT Crosses Below Key Moving Average Level (NASDAQ:SRPT) - January 26 at 6:02 AM logoSarepta Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRPT-US : January 23, 2017 (NASDAQ:SRPT) - January 23 at 10:13 PM logoKeep Politics Out Of Science, Says Departing FDA Chief (NASDAQ:SRPT) - January 23 at 10:13 PM


What is Sarepta Therapeutics' stock symbol?

Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."

Where is Sarepta Therapeutics' stock going? Where will Sarepta Therapeutics' stock price be in 2017?

19 equities research analysts have issued twelve-month price objectives for Sarepta Therapeutics' shares. Their predictions range from $5.00 to $106.00. On average, they anticipate Sarepta Therapeutics' share price to reach $62.00 in the next year.

When will Sarepta Therapeutics announce their earnings?

Sarepta Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February, 28th 2017.

What are analysts saying about Sarepta Therapeutics stock?

Here are some recent quotes from research analysts about Sarepta Therapeutics stock:

  • Needham & Company LLC analysts commented, "We expected the PRV would fetch a higher price, closer to $300M or more based on the sale price of the last two rare pediatric PRVs ($245M in May 2015 and $350M in August 2015). Sarepta sold the voucher through an auction-like process, implying that the market value for PRVs has softened. While the lower sales price leads to our modest price target reduction (to $78 from $81), we believe the more important outcome is that Sarepta should now have sufficient cash to reach positive cash flow from Exondys sales even if it sees more sluggish growth than we anticipate in 2017." (2/22/2017)
  • Robert W. Baird analysts commented, " (2/21/2017)
  • Oppenheimer Holdings, Inc. analysts commented, "We reiterate our BUY rating on shares of ISRG following Medtronic’s investor and analyst meeting on Monday. Medtronic provided details regarding its surgical robotic system for the first time. Given palpable investor concern about the prospects of MDT entering the robotic surgery fray, details given by MDT about its robotic surgery platform portended neutral to ISRG at worst, in our view. To wit, based on the details given during the meeting, including timing (seemingly at least 18-24 months away), ISRG should enjoy a clear field in the surgical robotics market over the near/ medium term. Importantly, MDT intimated its intended mode of growth in the robotic surgery space would initially be market development rather than competitive share. Indeed, noting >60% of surgeries are still performed in an open setting, MDT plans to target a vast array of general surgical procedures under-penetrated by robotic surgery yet well positioned for MIS techniques. While MDT will eventually target procedural markets in which ISRG does business (colorectal, thoracic), we believe growth opportunities for ISRG in the near/medium term are plentiful, primarily via domestic growth in general surgery procedures and international expansion of dvP and dvH, not to mention incremental opportunities portended by new products (i.e. SP). In sum, we maintain our bullish outlook on the stock, and reiterate our $700 year-end price target. Key notes on MDT’s upcoming platform: Engineering: The company’s robotics platform has been under development for ~3 years, with a large portion of the technology acquired via the Covidien merger." (6/3/2016)

Who owns Sarepta Therapeutics stock?

Sarepta Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include State Street Corp (4.83%), FMR LLC (2.19%), Two Sigma Investments LP (0.48%), Fred Alger Management Inc. (0.23%), Guggenheim Capital LLC (0.16%) and Highland Capital Management LP (0.16%). Company insiders that own Sarepta Therapeutics stock include David T Howton, Edward M Md Kaye, Jayant Aphale, M Kathleen Behrens and Sandesh Mahatme.

Who sold Sarepta Therapeutics stock? Who is selling Sarepta Therapeutics stock?

Sarepta Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, State Street Corp, Guggenheim Capital LLC, State Board of Administration of Florida Retirement System, National Planning Corp and United Capital Financial Advisers LLC. Company insiders that have sold Sarepta Therapeutics stock in the last year include David T Howton, Edward M Md Kaye, Jayant Aphale and Sandesh Mahatme.

Who bought Sarepta Therapeutics stock? Who is buying Sarepta Therapeutics stock?

Sarepta Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Highland Capital Management LP, Allianz Asset Management AG, Renaissance Technologies LLC, I.G. Investment Management LTD., AQR Capital Management LLC, Russell Investments Group Ltd. and Numeric Investors LLC.

How do I buy Sarepta Therapeutics stock?

Shares of Sarepta Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Sarepta Therapeutics stock cost?

One share of Sarepta Therapeutics stock can currently be purchased for approximately $32.02.

Sarepta Therapeutics (NASDAQ:SRPT) Chart for Sunday, February, 26, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Earnings History Chart

Earnings by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Dividend History Chart

Dividend Payments by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Last Updated on 2/26/2017 by Staff